CD163 and nonpapillary renal cell carcinoma: Among all groups of patients, ccRCC patients with high expression of both ERO1A and CD163 presented the highest TNM stage or Mayo Clinic stage, size, grade, and necrosis (SSIGN) score, as well as the shortest survival period.